T-Therapeutics Overview
- Year Founded
-
2022
- Status
-
Private
- Employees
-
66
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$133M
- Investors
-
15
T-Therapeutics General Information
Description
Operator of a biopharmaceutical company intended to develop engineered soluble biologics for oncological and immunological indications. The company's proprietary T cell receptors (TCR) discovery platform, a very heavily humanised mouse, which gives access to TCRs for human antigens that are not available from human samples, binds specific pMHC targets on target cells and recruits T cells to kill cancers or dampen down an immune response, enabling patients to improve their lives with chronic and infectious diseases.
Contact Information
Website
www.t-therapeutics.comCorporate Office
- One Granta, Granta Park
- Cambridge CB21 6DP
- England, United Kingdom
Corporate Office
- One Granta, Granta Park
- Cambridge CB21 6DP
- England, United Kingdom
T-Therapeutics Timeline
T-Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Early Stage VC (Series B) | 05-Nov-2026 | $133M | Completed | Startup | ||
| 3. Early Stage VC (Series A) | 21-Oct-2025 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series A) | 20-May-2025 | $39.9M | $39.9M | Completed | Pre-Clinical Trials | |
| 1. University Spin-Out | 10-May-2022 | Completed | Startup |
T-Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| SERIES A-2 | ||||||||
| Series A | ||||||||
| Series A | 428,571,480 | $0.000001 | $0.09 | $0.09 | 1x | $0.09 | 56.96% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
T-Therapeutics Comparisons
Industry
Financing
Details
T-Therapeutics Competitors (1)
One of T-Therapeutics’s competitors is Mestag Therapeutics, a Venture Capital-Backed company based in Cambridge, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Mestag Therapeutics | Venture Capital-Backed | Cambridge, United Kingdom |
T-Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
T-Therapeutics Patents
T-Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202506596-D0 | Immune modulating compositions | Pending | 30-Apr-2025 | ||
| WO-2026229471-A1 | Immune modulating compositions | Pending | 30-Apr-2025 | ||
| GB-202501476-D0 | Small non-aggregating immune ligand | Pending | 31-Jan-2025 | ||
| GB-202416862-D0 | Soluble non-aggregating immune ligand | Inactive | 15-Nov-2024 | ||
| GB-202415029-D0 | Soluble non-aggregating immune ligand | Inactive | 11-Oct-2024 |
T-Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
T-Therapeutics Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Advent Life Sciences | Venture Capital | Minority | ||
| British Business Bank | Lender/Debt Provider | Minority | ||
| Johnson & Johnson JJDC | Corporate Venture Capital | Minority | ||
| Lilly USA | Corporation | Minority | ||
| M Ventures | Corporate Venture Capital | Minority |
T-Therapeutics FAQs
-
When was T-Therapeutics founded?
T-Therapeutics was founded in 2022.
-
Where is T-Therapeutics headquartered?
T-Therapeutics is headquartered in Cambridge, United Kingdom.
-
What is the size of T-Therapeutics?
T-Therapeutics has 66 total employees.
-
What industry is T-Therapeutics in?
T-Therapeutics’s primary industry is Drug Discovery.
-
Is T-Therapeutics a private or public company?
T-Therapeutics is a Private company.
-
What is T-Therapeutics’s current revenue?
The current revenue for T-Therapeutics is .
-
How much funding has T-Therapeutics raised over time?
T-Therapeutics has raised $517M.
-
Who are T-Therapeutics’s investors?
Advent Life Sciences, British Business Bank, Johnson & Johnson JJDC, Lilly USA, and M Ventures are 5 of 15 investors who have invested in T-Therapeutics.
-
Who are T-Therapeutics’s competitors?
Mestag Therapeutics is a competitor of T-Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
